Abstract
Frailty has emerged as one of the most relevant clinical syndromes in older patients. This term relates to the loss of functional reserve that can occur in some older people following exposure to one or more low-intensity stressors placing them at high risk for developing a number of adverse outcomes such as disability, falls, hospitalization and death. Frailty is the outcome of two combined effects: the ageing process and other superimposed injuries like chronic disease or, indeed, psychological and social stressors. The mechanisms leading to frailty typically involve several systems: mainly hormones, oxidative stress, inflammation, immunity, and vascular system. One of the most outstanding pillars of the frailty syndrome is the loss of muscle quantity and function, referred to as sarcopenia. The main bulk of experimental pharmacological interventions addressing the clinical problem of frailty have been focused on the use of hormones, as replacement therapy in subjects with low or normal circulating basal levels of the hormone. Results have been disappointing, except for the case of testosterone that have shown some benefits. The effectiveness of other potential therapeutic interventions (antioxidants, anti-inflammatory agents, nutritional supplements) appears to be limited or has not been explored in detail until now. In conclusion, there is an available path to prevent the development of disability in older people through the treatment of frailty, its main risk factor. Aditional research and further experimental testing will help to identify new targets and help to make this journey successful.
Keywords: Frailty, concept, pathophysiology, pharmacological targets, treatment, RCTs.
Current Pharmaceutical Design
Title:Pharmaceutical Interventions for Frailty and Sarcopenia
Volume: 20 Issue: 18
Author(s): Olga Laosa, Cristina Alonso, Marta Castro and Leocadio Rodriguez-Manas
Affiliation:
Keywords: Frailty, concept, pathophysiology, pharmacological targets, treatment, RCTs.
Abstract: Frailty has emerged as one of the most relevant clinical syndromes in older patients. This term relates to the loss of functional reserve that can occur in some older people following exposure to one or more low-intensity stressors placing them at high risk for developing a number of adverse outcomes such as disability, falls, hospitalization and death. Frailty is the outcome of two combined effects: the ageing process and other superimposed injuries like chronic disease or, indeed, psychological and social stressors. The mechanisms leading to frailty typically involve several systems: mainly hormones, oxidative stress, inflammation, immunity, and vascular system. One of the most outstanding pillars of the frailty syndrome is the loss of muscle quantity and function, referred to as sarcopenia. The main bulk of experimental pharmacological interventions addressing the clinical problem of frailty have been focused on the use of hormones, as replacement therapy in subjects with low or normal circulating basal levels of the hormone. Results have been disappointing, except for the case of testosterone that have shown some benefits. The effectiveness of other potential therapeutic interventions (antioxidants, anti-inflammatory agents, nutritional supplements) appears to be limited or has not been explored in detail until now. In conclusion, there is an available path to prevent the development of disability in older people through the treatment of frailty, its main risk factor. Aditional research and further experimental testing will help to identify new targets and help to make this journey successful.
Export Options
About this article
Cite this article as:
Laosa Olga, Alonso Cristina, Castro Marta and Rodriguez-Manas Leocadio, Pharmaceutical Interventions for Frailty and Sarcopenia, Current Pharmaceutical Design 2014; 20 (18) . https://dx.doi.org/10.2174/13816128113196660705
DOI https://dx.doi.org/10.2174/13816128113196660705 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Strategies to Delineate Matrix Metalloproteinase (MMP)-Substrate Relationships and Identify Targets to Block MMP Activity
Mini-Reviews in Medicinal Chemistry A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Current Alzheimer Research Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Long Term Safety and Efficacy of Internal Carotid Artery Adventitial Stripping in Carotid Sinus Syndrome
Current Hypertension Reviews Insulin Therapy, Insulin Resistance and Vascular Dysfunction
Current Vascular Pharmacology Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Leukotrienes and Atherosclerosis
Current Drug Targets Hemodialysis Membranes for Acute and Chronic Renal Insufficiency
Current Neurovascular Research Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Current Vascular Pharmacology Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Current Neuropharmacology Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Levosimendan Preoperative
Current Pharmaceutical Design The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews